Sanofi (SNY)
Pharmaceutical Preparations · market cap $50.8B · as of 2026-10-16
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-11-25 (est.)Phase 3 · Rilzabrutinibimp 9/10
- 2026-11-25PDUFA · Venglustatimp 9/10
- 2026-11-28 (est.)Phase 3 · Measles, combinations with mumps and rubella, live attenuatedimp 9/10
- 2026-12-01 (est.)Phase 2 · Pandemic flu H5 HA mRNA SD2 vaccineimp 7/10
- 2026-12-01 (est.)Phase 3 · PCV21imp 9/10
- 2026-12-17 (est.)Phase 2 · SAR442970imp 7/10
- 2026-12-23 (est.)Phase 2 · Frexalimabimp 7/10
- 2026-12-31 (est.)Phase 2 · Isatuximabimp 7/10
| Asset | Phase | Indication |
|---|---|---|
| SR147778 | Phase 2 | Obesity |
| XRP0038 (NV1FGF) | Phase 2 | Peripheral Arterial Disease |
| efanesoctocog alfa (BIVV001) | Phase 3 | Hemophilia A |
| Duvakitug | Phase 3 | Ulcerative Colitis |
| xaliproden (SR57746A) | Phase 3 | Alzheimer Disease |
| zolpidem-MR (SL800750) | Phase 3 | Sleep Initiation and Maintenance Disorders |
| A/H1N1 pandemic influenza vaccine (non- adjuvanted) | Phase 3 | Influenza |
| CYD dengue vaccine serotypes (1, 2, 3, 4) | Phase 2 | Dengue Virus |
| lactoserum | Phase 3 | Hygiene |
| DTaP-IPV-HB-PRP~T | Phase 3 | Diphtheria |
| Yellow fever vaccine (live) | Phase 3 | Yellow Fever Immunization |
| G-CSF Plus Plerixafor | Phase 2 | Hodgkin's Disease |
| SAR443122 | Phase 2 | Colitis Ulcerative |
| Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus | Phase 3 | Dengue |
| epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile | Phase 3 | Breast Neoplasms |
| Low Dose (LD) RSVt vaccine | Phase 3 | RSV Immunisation |
| Insulin glargine/lixisenatide fixed ratio combination | Phase 3 | Type 2 Diabetes Mellitus |
| RSV vaccine candidate | Phase 2 | Respiratory Syncytial Virus Infection |
| Fexofenadine | Phase 3 | Seasonal Allergic Rhinitis |
| rimonabant (SR141716) | Phase 3 | Obesity |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for SNY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
